Patents by Inventor Aurelien MAZERAUD

Aurelien MAZERAUD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING SEPSIS WITH SYNAPTIC VESICLE 2A AND/OR 2B BINDING CHEMICAL ENTITIES
    Publication number: 20220233503
    Abstract: Methods of treating sepsis induced acute brain dysfunction (SiBD), comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. Methods of reducing sepsis mortality, comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. In some embodiments the synaptic vesicle 2a and/or 2b binding chemical entity is a synaptic vesicle 2a and/or 2b modulator such as agonist, partial agonist, antagonist or partial antagonist. In some embodiments the synaptic vesicle 2a and/or 2b binding chemical entity is levetiracetam or a derivative or analogue of levetiracetam. In some embodiments the synaptic vesicle 2a binding chemical entity is levetiracetam.
    Type: Application
    Filed: March 23, 2022
    Publication date: July 28, 2022
    Applicant: INSTITUT PASTEUR
    Inventors: Tarek SHARSHAR, Fabrice CHRETIEN, Aurelien MAZERAUD, Fernando Augusto BOZZA
  • METHODS OF TREATING SEPSIS WITH SYNAPTIC VESICLE 2A AND/OR 2B BINDING CHEMICAL ENTITIES
    Publication number: 20200121644
    Abstract: Methods of treating sepsis induced acute brain dysfunction (SiBD), comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. Methods of reducing sepsis mortality, comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. In some embodiments the synaptic vesicle 2a and/or 2b binding chemical entity is a synaptic vesicle 2a and/or 2b modulator such as agonist, partial agonist, antagonist or partial antagonist. In some embodiments the synaptic vesicle 2a and/or 2b binding chemical entity is levetiracetam or a derivative or analogue of levetiracetam. In some embodiments the synaptic vesicle 2a binding chemical entity is levetiracetam.
    Type: Application
    Filed: May 19, 2017
    Publication date: April 23, 2020
    Inventors: Tarek SHARSHAR, Fabrice CHRETIEN, Aurelien MAZERAUD, Fernando Augusto BOZZA